GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

Bain Capital-backed Korea Zinc has raised its share-buyback offer to frustrate a takeover bid by Seoul-based private-equity firm MBK Partners, in a battle for control over the world's largest zinc ...

ShareUK pharmaceutical giant, GSK said it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

U.S.: Stocks slide as eager investors scale back hopes of jumbo Fed rate cuts After setting a ... of claims in U.S. courts ...

0544 ET – GSK’s $2.2 billion settlement to resolve the majority of Zantac litigation cases was welcomed by the market, with ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

The FTSE 100 index closed down 6.01 points, 0.1%, at 8,237.73. The FTSE 250 ended 114.01 points lower, 0.6%, at 20,708.37, and the AIM All-Share fell 2.13 points, 0.3%, to 734.53.

The UK's main stock indexes slipped on Thursday as some of the companies traded without the entitlement of their dividend pay ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

The UK FTSE 100 index increased by 0.3%, driven by significant gains in GSK following a settlement in the U.S. The market ...

GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at 0754 ...